Načítá se...
Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation
TRAIL-activating therapy is promising in treating various cancers, including pancreatic cancer, a highly malignant neoplasm with poor prognosis. However, many pancreatic cancer cells are resistant to TRAIL-induced apoptosis despite their expression of intact death receptors (DRs). Protein O-GlcNAcyl...
Uloženo v:
| Vydáno v: | Lab Invest |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183418/ https://ncbi.nlm.nih.gov/pubmed/31896813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41374-019-0365-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|